Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04288323 · ClinicalTrials.gov registry record · Phase 4
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT04288323 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 79 participants.
The verdict
NCT04288323, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.
Interventions
- DRUG Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2018-04-27 |
| Est. Completion | 2025-12-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04288323
The ClinicalTrials.gov registry entry for NCT04288323 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid is the first listed.
NCT04288323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04288323 about?
NCT04288323 is a clinical study titled "Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis". This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.
What is the current status of trial NCT04288323?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2018-04-27. Estimated completion is 2025-12-16.
What interventions are being tested in trial NCT04288323?
The interventions under investigation include: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (DRUG).
Who is sponsoring clinical trial NCT04288323?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.